<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04347005</url>
  </required_header>
  <id_info>
    <org_study_id>AR882-101</org_study_id>
    <nct_id>NCT04347005</nct_id>
  </id_info>
  <brief_title>The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Rising Dose Study of AR882, a Potent Uricosuric Agent, in Healthy Adult Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arthrosi Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arthrosi Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled, single ascending dose study of AR882 in
      healthy adult males.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 22, 2019</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety profile of AR882 based on incidence of abnormal laboratory findings</measure>
    <time_frame>8 Days</time_frame>
    <description>Analysis of abnormal safety laboratory findings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>8 Days</time_frame>
    <description>ECG Heart Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>8 Days</time_frame>
    <description>ECG PR-Interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>8 Days</time_frame>
    <description>ECG RR-Interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>8 Days</time_frame>
    <description>ECG QRS-Interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>8 Days</time_frame>
    <description>ECG QT-Interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>8 Days</time_frame>
    <description>ECG QTc-Interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>8 Days</time_frame>
    <description>Vital Sign - Systolic Blood Pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>8 Days</time_frame>
    <description>Vital Sign - Diastolic Blood Pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>8 Days</time_frame>
    <description>Vital Sign - Pulse Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>8 Days</time_frame>
    <description>Vital Sign - Body Temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>8 Days</time_frame>
    <description>Vital Sign - Respiratory Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) for plasma AR882</measure>
    <time_frame>6 Days</time_frame>
    <description>Profile from plasma in terms of AUC for AR882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) for AR882</measure>
    <time_frame>6 Days</time_frame>
    <description>Profile from plasma in terms of Tmax for AR882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) for AR882</measure>
    <time_frame>6 Days</time_frame>
    <description>Profile from plasma in terms of Cmax for AR882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal half-life (t1/2) for AR882</measure>
    <time_frame>6 Days</time_frame>
    <description>Profile from plasma in terms of t1/2 for AR882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount excreted (Ae) into urine for AR882</measure>
    <time_frame>6 Days</time_frame>
    <description>Profile from urine in terms of Ae for AR882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fractional Excretion (FEUA) for AR882</measure>
    <time_frame>6 Days</time_frame>
    <description>Profile from urine in terms of FEUA for AR882</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PD profile of a single dose of AR882</measure>
    <time_frame>6 Days</time_frame>
    <description>Profile from serum uric acid concentrations over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD profile of a single dose of AR882 in combination with allopurinol</measure>
    <time_frame>6 Days</time_frame>
    <description>Profile from serum uric acid concentrations over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD profile of a single dose of AR882 in combination with febuxostat</measure>
    <time_frame>6 Days</time_frame>
    <description>Profile from serum uric acid concentrations over time</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>AR882 (Dose A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AR882 (Dose B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AR882 (Dose C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AR882 (Dose D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AR882 (Dose E)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AR882 (Dose B) Solid Oral Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 1: AR882</intervention_name>
    <description>Single dose of AR882 or matching placebo</description>
    <arm_group_label>AR882 (Dose A)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 2: AR882</intervention_name>
    <description>Single dose of AR882 or matching placebo</description>
    <arm_group_label>AR882 (Dose B)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 3: AR882</intervention_name>
    <description>Single dose of AR882 or matching placebo</description>
    <arm_group_label>AR882 (Dose C)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 4: AR882</intervention_name>
    <description>Single dose of AR882 or matching placebo</description>
    <arm_group_label>AR882 (Dose D)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 5: AR882</intervention_name>
    <description>Single dose of AR882 or matching placebo</description>
    <arm_group_label>AR882 (Dose E)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 6: AR882 Food Effect</intervention_name>
    <description>Single dose of AR882 or matching placebo in a fed state</description>
    <arm_group_label>AR882 (Dose B)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 7: AR882 Solid Oral Formulation</intervention_name>
    <description>Single dose of AR882 or matching placebo</description>
    <arm_group_label>AR882 (Dose B) Solid Oral Formulation</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 8: AR882 in combination with allopurinol</intervention_name>
    <description>Single dose of allopurinol alone and a single dose of AR882 in combination with a single dose of allopurinol</description>
    <arm_group_label>AR882 (Dose B)</arm_group_label>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 9: AR882 in combination with febuxostat</intervention_name>
    <description>Single dose of febuxostat alone and a single dose of AR882 in combination with a single dose of febuxostat</description>
    <arm_group_label>AR882 (Dose B)</arm_group_label>
    <arm_group_label>Febuxostat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Serum uric acid level ≥ 4.5 mg/dL (268 µmol/L)

          -  Body weight no less than 50 kg and body mass index (BMI) within the range of ≥18 and
             ≤33 kg/m2

          -  Must be free of any clinically significant disease that requires a physician's care
             and/or would interfere with study evaluations or procedures

        Exclusion Criteria:

          -  Malignancy within 5 years, except for successfully treated basal or squamous cell
             carcinoma of the skin

          -  History of cardiac abnormalities

          -  History and/or presence of drug addiction or excessive use of alcohol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nucleus Network Pty, Ltd.</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

